Guichard N, Guillarme D, Bonnabry P, Fleury-Souverain S (2017) Antineoplastic drugs and their analysis: a state of the art review. Analyst 142:2273–2321. https://doi.org/10.1039/c7an00367f

Article  CAS  PubMed  Google Scholar 

Cronstein BN (1996) Molecular therapeutics. methotrexate and its mechanism of action. Arthritis Rheum 39:1951–1960. https://doi.org/10.1002/art.1780391203

Article  CAS  PubMed  Google Scholar 

Taylor ZL, Vang J, Lopez-Lopez E, Oosterom N, Mikkelsen T, Ramsey LB (2021) Systematic review of pharmacogenetic factors that influence high-dose methotrexate pharmacokinetics in pediatric malignancies. Cancers (Basel) 13:2837. https://doi.org/10.3390/cancers13112837

Article  CAS  Google Scholar 

Methotrexate (Jiangsu Hengrui Pharmaceutical Co., LTD): drug information

Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN, Coblyn JS (1988) Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 31:167–175. https://doi.org/10.1002/art.1780310203

Article  CAS  Google Scholar 

Morgan C, Lunt M, Brightwell H, Bradburn P, Fallow W, Lay M, Silman A, Bruce IN (2003) Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis 62:15–19. https://doi.org/10.1136/ard.62.1.15

Article  CAS  PubMed  Google Scholar 

American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932–2947. https://doi.org/10.1200/JCO.2006.06.9591

Article  CAS  Google Scholar 

Ramsey LB, Balis FM, MM, Schmiegelow K, Pauley JL, Bleyer A, Widemann BC, Askenazi D, Bergeron S, Shirali A, Schwartz S, Vinks AA, Heldrup J, (2018) Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist 23:52–61. https://doi.org/10.1634/theoncologist.2017-0243

Article  CAS  PubMed  Google Scholar 

Shen DD, Azarnoff DL (1978) Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 3:1–13. https://doi.org/10.2165/00003088-197803010-00001

Article  CAS  Google Scholar 

Paci A, Veal G, Bardin C, Levêque D, Widmer N, Beijnen J, Astier A, Chatelut E (2014) Review of therapeutic drug monitoring of anticancer drugs part 1 – cytotoxics. Eur J Cancer 50:2010–2019. https://doi.org/10.1016/j.ejca.2014.04.014

Article  CAS  PubMed  Google Scholar 

Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS (2012) High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol 73:106–114. https://doi.org/10.1111/j.1365-2125.2011.04054.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabot C, Debord J, Roullet B, Marquet P, Merle L, Lachatre G (1995) Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics. Int J Clin Pharmacol Ther 33:164–169

CAS  PubMed  Google Scholar 

Sheiner LB, Rosenberg B, Melmon KL (1972) Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 5:411–459. https://doi.org/10.1016/0010-4809(72)90051-1

Article  CAS  PubMed  Google Scholar 

Lu X, Xu G, Chen L, Fan J, Li M, Zhu L (2020) Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations. Eur J Clin Pharmacol 76:695–702. https://doi.org/10.1007/s00228-020-02840-0

Article  CAS  Google Scholar 

Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M, German-Austrian-Swiss ALL-BFM Study Group (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:4477–4489. https://doi.org/10.1182/blood-2007-09-112920

Article  CAS  Google Scholar 

Reiter A, Tiemann M, Ludwig WD, Wacker HH, Yakisan E, Schrappe M, Henzler D, Sykora KW, Brandt A, Odenwald E (1994) NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin’s lymphomas in children and adolescents. Part 1: classification and allocation to strategic therapy groups. BIF study group Klin Pädiatr 206:222–233. https://doi.org/10.1055/s-2008-1046608

Article  CAS  Google Scholar 

Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332:901–906. https://doi.org/10.1056/NEJM199504063321401

Article  CAS  Google Scholar 

Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O’Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ (1993) Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225–1230. https://doi.org/10.1056/NEJM199310213291703

Article  CAS  PubMed  Google Scholar 

Tugwell P, Bennett K, Gent M (1987) Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Intern Med 107:358–366. https://doi.org/10.7326/0003-4819-107-2-358

Article  CAS  PubMed  Google Scholar 

Uemura O, Honda M, Matsuyama T, Ishikura K, Hataya H, Yata N, Nagai T, Ikezumi Y, Fujita N, Ito S, Iijima K, Kitagawa T (2011) Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. Clin Exp Nephrol 15:694–699. https://doi.org/10.1007/s10157-011-0452-y

Article  CAS  PubMed  Google Scholar 

Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41. https://doi.org/10.1159/000180580

Article  CAS  PubMed  Google Scholar 

Burns DR, Elswick RK (2001) Equivalence testing with dental clinical trials. J Dent Res 80:1513–1517. https://doi.org/10.1177/00220345010800060701

Article  CAS  Google Scholar 

Wright KD, Stewart CF (2015) Response to: comment on ‘Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.’ Cancer Chemother Pharmacol 75:877–878. https://doi.org/10.1007/s00280-015-2699-6

Article  PubMed  Google Scholar 

Beechinor RJ, Thompson PA, Hwang MF, Vargo RC, Bomgaars LR, Gerhart JG, Dreyer ZE, Gonzalez D (2019) The population pharmacokinetics of high-dose methotrexate in infants with acute lymphoblastic leukemia highlight the need for bedside individualized dose adjustment: a report from the Children’s Oncology Group. Clin Pharmacokinet 58:899–910. https://doi.org/10.1007/s40262-018-00734-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panetta JC, Roberts JK, Huang J, Lin T, Daryani VM, Harstead KE, Patel YT, Onar-Thomas A, Campagne O, Ward DA, Broniscer A, Robinson G, Gajjar A, Stewart CF (2020) Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. Br J Clin Pharmacol 86:362–371. https://doi.org/10.1111/bcp.14160

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi ZY, Liu YO, Gu HY, Xu XQ, Yan C, Yang XY, Yan D (2020) Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma. Biopharm Drug Dispos 41:101–110. https://doi.org/10.1002/bdd.2221

Article  CAS  PubMed  Google Scholar 

Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, Xuan K, Leblond V, Lechat P (2006) Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol 58:626–633. https://doi.org/10.1007/s00280-006-0202-0

Article  CAS  PubMed  Google Scholar 

Fukuhara K, Ikawa K, Morikawa N, Kumagai K (2008) Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther 33:677–684. https://doi.org/10.1111/j.1365-2710.2008.00966.x

Article  CAS  PubMed  Google Scholar 

Min Y, Qiang F, Peng L, Zhu Z (2009) High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. Biopharm Drug Dispos 30:437–447. https://doi.org/10.1002/bdd.678

Article  CAS  Google Scholar 

Simon N, Marsot A, Villard E, Choquet S, Hoang-Xuan K, Zahr N, Lechat P, Leblond V, Hulot JS (2013) Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenom J13:507–513. https://doi.org/10.1038/tpj.2012.37

Article  CAS  Google Scholar 

Benz-de Bretagne I, Zahr N, Le Gouge A, Hulot JS, Houillier C, Hoang-Xuan K, Gyan E, Lissandre S, Choquet S, Le Guellec C (2014) Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance. Br J Clin Pharmacol 78:329–342. https://doi.org/10.1111/bcp.12326

Article  CAS  Google Scholar 

Watanabe M, Fukuoka N, Takeuchi T, Yamaguchi K, Motoki T, Tanaka H, Kosaka S, Houchi H (2014) Developing population pharmacokinetic parameters for high-dose methotrexate therapy: implication of correlations among developed parameters for individual parameter estimation using the Bayesian least-squares method. Biol Pharm Bull 37:916–921. https://doi.org/10.1248/bpb.b13-00672

Article  CAS  PubMed  Google Scholar 

Nader A, Zahran N, Alshammaa A, Altaweel H, Kassem N, Wilby KJ (2017) Population pharmacokinetics of intravenous methotrexate in patients with hematological malignancies: utilization of routine clinical monitoring parameters. Eur J Drug Metab Pharmacokinet 42:221–228. https://doi.org/10.1007/s13318-016-0338-1

Article  CAS  PubMed